Replies to post #169201 on Biotech Values

[genisi]

Since I follow the HCV space as an investor I would choose to wait (if able) for a better oral option

And if you were a GT1 treatment-naïve patient, would you take ABBV's regimen or GILD's (assuming 12 weeks treatment and SVRs are in the same ballpark)? and what if GILD's ION-3 trial shows that 8 week regimen is enough?